ImmunoGen to Present Initial Data from FORWARD II Expansion Cohort of Mirvetuximab Soravtansine in Combination with KEYTRUDA ...
October 08 2018 - 6:05PM
Business Wire
ImmunoGen, Inc., (Nasdaq: IMGN), a leader in the expanding field
of antibody-drug conjugates (ADCs) for the treatment of cancer,
today announced that initial findings from the FORWARD II expansion
cohort of mirvetuximab soravtansine in combination with Merck’s
anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), will be presented at
the European Society for Medical Oncology (ESMO) Congress from
October 19-23, 2018 in Munich, Germany. The poster will include
initial safety and preliminary anti-tumor activity for 46 patients
with platinum-resistant ovarian cancer (PROC), of whom 35 have
medium or high folate receptor alpha (FRα) expression.
Encouraging activity and favorable tolerability data from the
FORWARD II dose-escalation cohort assessing mirvetuximab
soravtansine in combination with KEYTRUDA in 14 heavily pre-treated
patients with platinum-resistant epithelial ovarian cancer (EOC)
were presented in March at the Society of Gynecologic Oncology
(SGO) Annual Meeting. These findings supported enrollment of
additional patients in an expansion cohort with full doses of both
agents to further evaluate this combination in PROC.
“Based on the data presented at SGO, we advanced mirvetuximab
soravtansine plus pembrolizumab into an expansion cohort focusing
on PROC patients with medium and high FRα expression,” said Anna
Berkenblit, M.D., Vice President and Chief Medical Officer of
ImmunoGen. “We look forward to presenting initial findings at ESMO,
as we evaluate several combinations that may ultimately enable us
to treat more women with ovarian cancer.”
Details of ImmunoGen’s poster presentation are as follows:
Title: “Mirvetuximab soravtansine, a folate receptor
alpha (FRα)-targeting antibody-drug conjugate (ADC), with
pembrolizumab in platinum-resistant ovarian cancer (PROC): Initial
results of an expansion cohort from FORWARD II, a Phase Ib study”
(presentation number 949P)Date: October 20, 2018Time:
12:30 CESTLead author: Ursula Matulonis, M.D., Director and
Program Leader, Gynecologic Oncology Program, Dana-Farber Cancer
Institute, Boston, MA
Mirvetuximab soravtansine is an ADC comprised of a FRα-binding
humanized antibody linked to the tubulin-disrupting maytansinoid
DM4. This agent activates monocytes and upregulates immunogenic
cell death markers on ovarian tumor cells, providing a rationale
for combining with immune checkpoint blockade. Mirvetuximab
soravtansine is being evaluated in combination with pembrolizumab
in patients with PROC.
Additional information can be found at www.esmo.org.
ABOUT IMMUNOGENImmunoGen is developing the next
generation of antibody-drug conjugates (ADCs) to improve outcomes
for cancer patients. By generating targeted therapies with enhanced
anti-tumor activity and favorable tolerability profiles, we aim to
disrupt the progression of cancer and offer our patients more good
days. We call this our commitment to “target a better now.” Our
lead product candidate, mirvetuximab soravtansine, is in a Phase 3
study for folate receptor alpha (FRα)-positive platinum resistant
ovarian cancer, and in Phase 1b/2 testing in combination regimens.
Our novel IGN candidates for hematologic malignancies, IMGN779 and
IMGN632, are in Phase 1 studies.
Learn more about who we are, what we do, and how we do it at
www.immunogen.com.
KEYTRUDA® is a registered trademark of Merck Sharp & Dohme
Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ,
USA.
This press release includes forward-looking statements based on
management's current expectations. These statements include, but
are not limited to, ImmunoGen's ability to expand the addressable
patient population for mirvetuximab soravtansine and the regulatory
and commercial potential of mirvetuximab combinations in earlier
lines of therapy. For these statements, ImmunoGen claims the
protection of the safe harbor for forward-looking statements
provided by the Private Securities Litigation Reform Act of 1995.
Various factors could cause ImmunoGen's actual results to differ
materially from those discussed or implied in the forward-looking
statements, and you are cautioned not to place undue reliance on
these forward-looking statements, which are current only as of the
date of this release. It should be noted that there are risks and
uncertainties related to the development of novel anticancer
products, including risks related to preclinical and clinical
studies, their timings and results, and the potential that earlier
clinical studies may not be predictive of future results. A review
of these risks can be found in ImmunoGen's Annual Report on Form
10-K for the year ended December 31, 2017 and other reports filed
with the Securities and Exchange Commission.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20181008005725/en/
INVESTOR RELATIONS CONTACTImmunoGen, Inc.Sarah Kiely,
781-895-0600sarah.kiely@immunogen.comorMEDIA
CONTACTImmunoGen, Inc.Courtney O’Konek,
781-895-0600courtney.okonek@immunogen.comorFTI ConsultingRobert
Stanislaro, 212-850-5657robert.stanislaro@fticonsulting.com
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Apr 2023 to Apr 2024